Skip to main content
SpringerLink
Log in

Prävention

N-Acetylcystein: neue Option zur frühen Bekämpfung von Schizophrenie

  • Fortbildung
  • Published:
DNP - Der Neurologe & Psychiater Aims and scope

Symptomfreiheit sowie Erhalt der Selbstbestimmung über die eigene Lebensführung gehören zu den Zielen der Schizophreniebehandlung. Die erreichten Genesungsraten sind jedoch eher moderat, was sich auch in den langfristigen Kosten für das Gesundheitssystem widerspiegelt. Die Prävention der Schizophrenie, mit dem Ziel attenuierte psychotische Symptome zu diagnostizieren, bevor eine manifeste Schizophrenie auftritt, steht daher im Fokus von Forschung und Praxis. Dazu gehören auch früh einsetzbare moderne Behandlungsmethoden mit geringem Nebenwirkungsprofil wie N-Acetylcystein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, „just the facts“ what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008;102:1–18.

    Article  PubMed  Google Scholar 

  2. Jääskeläinen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin. 2013;39:1296–1306.

    Article  PubMed  Google Scholar 

  3. World Health Organisation. The Global burden of disease: 2004 update. Geneva, Switzerland: World Health Organization; 2004.

  4. Frey S. The economic burden of schizophrenia in Germany: A population-based retrospective cohort study using genetic matching. European Psychiatry. 2014;29:479–489.

    Article  CAS  PubMed  Google Scholar 

  5. Campion J, Bhui K, Bhugra D. European Psychiatric Association (EPA) guidance on prevention of mental disorders. European Psychiatry. 2012;27:68–80.

    Article  CAS  PubMed  Google Scholar 

  6. Seidman LJ, Nordentoft M. New Targets for Prevention of Schizophrenia: Is It Time for Interventions in the Premorbid Phase? Schizophrenia Bulletin. 2015;41:795–800.

    Article  PubMed  PubMed Central  Google Scholar 

  7. American Psychiatric Association. Diagnostisches und Statistisches Manual Psychischer Störungen - DSM-5; 2015.

  8. Ruhrmann S, Klosterkötter J, Bodatsch M, Bechdolf A, Schimmelmann BG, Nikolaides A, et al. Pharmacological Prevention and Treatment in Clinical At-Risk States for Psychosis. Current Pharmaceutical Design. 2012;18:550–557.

    Article  CAS  PubMed  Google Scholar 

  9. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RKR, Riecher-Rössler A, et al. EPA guidance on the early intervention in clinical high risk states of psychoses. European Psychiatry. 2015;30:388–404.

    Article  CAS  PubMed  Google Scholar 

  10. DGPPN. S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Darmstadt: Steinkopff; 2006.

  11. National Institute for Health Care Excellence. Psychosis and Schizophrenia in adults. The NICE guideline on treatment and management; 2014.

  12. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209–1222.

    Article  PubMed  Google Scholar 

  13. Sommer IEC, Slotema CW, Daskalakis ZJ, Derks EM, Blom JD, van der Gaag M. The treatment of hallucinations in schizophrenia spectrum disorders. Schizophrenia Bulletin. 2012;38:704–714.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Li P, L. Snyder G, E. Vanover K. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. CTMC. 2016;16:3385–3403.

    Article  CAS  Google Scholar 

  15. Nowak I, Sabariego C, Œwitaj P, Anczewska M. Disability and recovery in schizophrenia: A systematic review of cognitive behavioral therapy interventions. BMC Psychiatry. 2016;16:1–15.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kirschner M, Aleman A, Kaiser S. Secondary negative symptoms - A review of mechanisms, assessment and treatment. Schizophr Res. 2017;186:29–38.

    Article  PubMed  Google Scholar 

  17. Remington G, Agid O, Foussias G, Fervaha G, Takeuchi H, Lee J, Hahn M. What does schizophrenia teach us about antipsychotics? Can J Psychiatry. 2015;60:S14–8.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Morrison AP, Turkington D, Pyle M, Spencer H, Brabban A, Dunn G, et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: A single-blind randomised controlled trial. The Lancet. 2014;383:1395–1403.

    Article  Google Scholar 

  19. Anderson JP, Icten Z, Alas V, Benson C, Joshi K. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry. 2017;17:1–10.

    Article  Google Scholar 

  20. Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–468.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Thase ME, Kingdon D, Turkington D. The promise of cognitive behavior therapy for treatment of severe mental disorders: A review of recent developments. World psychiatry. 2014;13:244–250.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Pankowski D, Kowalski J, Gaweda L. The effectiveness of metacognitive training for patients with schizophrenia: a narrative systematic review of studies published between 2009 and 2015. Psychiatr Pol. 2016;50:787–803.

    Article  PubMed  Google Scholar 

  23. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: Methodology and effect sizes. Am J Psychiatry. 2011;168:472–485.

    Article  PubMed  Google Scholar 

  24. Fiszdon JM, Reddy LF. Review of social cognitive treatments for psychosis. Clin Psychol Rev. 2012;32:724–740.

    Article  PubMed  Google Scholar 

  25. Medalia A, Saperstein AM. Does cognitive remediation for schizophrenia improve functional outcomes? Current Opinion in Psychiatry. 2013;26:151–157.

    Article  PubMed  Google Scholar 

  26. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry. 1987;44:660–669.

    Article  CAS  PubMed  Google Scholar 

  27. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? British medical journal (Clinical research ed.). 1988;296:681–682.

    Article  Google Scholar 

  28. Weinberger DR, Harrison P, editors. Schizophrenia, 3rd Edition. 3rd ed.: Wiley-Blackwell; 2011.

  29. Millan MJ, Andrieux A, Bartzokis G, Cadenhead K, Dazzan P, Fusar-Poli P, et al. Altering the course of schizophrenia: progress and perspectives. Nature Reviews Neuroscience. 2016:1–31.

  30. Brown AS. The environment and susceptibility to schizophrenia. Progress in neurobiology. 2011;93:23–58.

    Article  CAS  PubMed  Google Scholar 

  31. Hardingham GE, Do KQ. Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nature Reviews Neuroscience. 2016:1–9.

  32. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic to Omnigenic. Cell. 2017;169:1177–1186.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ursini G, Punzi G, Chen Q, Marenco S, Robinson J, Porcelli A, et al. Placental gene expression mediates the interaction between obstetrical history and genetic risk for schizophrenia. bioRxiv. 2017:1–41.

  34. Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends in Neurosciences. 2012;35:57–67.

    Article  CAS  PubMed  Google Scholar 

  35. Insel TR. Rethinking schizophrenia. Nature. 2010;468:187–193.

    Article  CAS  PubMed  Google Scholar 

  36. Mighdoll MI, Tao R, Kleinman JE, Hyde TM. Myelin, myelin-related disorders, and psychosis. Schizophr Res. 2015;161:85–93.

    Article  PubMed  Google Scholar 

  37. Monin A, Baumann PS, Griffa A, Xin L, Mekle R, Fournier M, et al. Glutathione deficit impairs myelin maturation: Relevance for white matter integrity in schizophrenia patients. Molecular Psychiatry. 2015;20:827–838.

    Article  CAS  PubMed  Google Scholar 

  38. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proceedings of the National Academy of Sciences of the United States of America. 2007;104:16621–16626.

    Article  CAS  Google Scholar 

  39. Walterfang M, Wood SJ, Velakoulis D, Copolov D, Pantelis C. Diseases of White Matter and Schizophrenia-Like Psychosis. Australian & New Zealand Journal of Psychiatry. 2016;39:746–756.

    Article  Google Scholar 

  40. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends in pharmacological sciences. 2013;34:167–177.

    Article  CAS  PubMed  Google Scholar 

  41. Skvarc DR, Dean OM, Byrne LK, Gray L, Lane S, Lewis M, et al. The effect of N-acetylcysteine (NAC) on human cognition - A systematic review. Neuroscience and Biobehavioral Reviews. 2017;78:44–56.

    Article  CAS  PubMed  Google Scholar 

  42. Emiliani FE, Sedlak TW, Sawa A. Oxidative stress and schizophrenia: Recent breakthroughs from an old story. Current Opinion in Psychiatry. 2014;27:185–190.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: A novel treatment target in psychiatry. Trends in pharmacological sciences. 2008;29:346–351.

    Article  CAS  PubMed  Google Scholar 

  44. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. Journal of neurochemistry. 2003;84:1173–1183.

    Article  CAS  PubMed  Google Scholar 

  45. Arakawa M, Ito Y. N-acetylcysteine and neurodegenerative diseases: Basic and clinical pharmacology. Cerebellum. 2007;6:308–314.

    Article  CAS  PubMed  Google Scholar 

  46. Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2013;46:200–206.

    Article  CAS  Google Scholar 

  47. Monin A, Fournier M, Baumann PS, Cuénod M, Do KQ. Role of Redox Dysregulation in White Matter Anomalies Associated with Schizophrenia. In: Modeling the Psychopathological Dimensions of Schizophrenia - From Molecules to Behavior: Elsevier; 2016. p. 481–500.

    Google Scholar 

  48. Soria FN, Zabala A, Pampliega O, Palomino A, Miguelez C, Ugedo L, et al. Cystine/glutamate antiporter blockage induces myelin degeneration. Glia. 2016;64:1381–1395.

    Article  PubMed  Google Scholar 

  49. Baker DA, Madayag A, Kristiansen LV, Meador-Woodruff JH, Haroutunian V, Raju I. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology. 2008;33:1760–1772.

    Article  CAS  PubMed  Google Scholar 

  50. Baker DA, Xi Z, Shen H, Swanson CJ, Kalivas PW. The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate. The Journal of Neuroscience. 2002;22:9134–9141.

    Article  CAS  PubMed  Google Scholar 

  51. Simpson EH, Kellendonk C, Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron. 2010;65:585–596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Phensy A, Duzdabanian HE, Brewer S, Panjabi A, Driskill C, Berz A, et al. Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment. Frontiers in behavioral neuroscience. 2017;11:1–17.

  53. Rapado-Castro M, Dodd S, Bush AI, Malhi GS, Skvarc DR, On ZX, et al. Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychological Medicine. 2017;47:866–876.

    Article  CAS  PubMed  Google Scholar 

  54. Rapado-Castro M, Berk M, Venugopal K, Bush AI, Dodd S, Dean OM. Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. 2015;57:69–75.

    Article  CAS  Google Scholar 

  55. Asevedo E, Cunha GR, Zugman A, Mansur RB, Brietzke E. N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals. Reviews in the neurosciences. 2012;23:353–362.

    Article  CAS  PubMed  Google Scholar 

  56. Yung AR, McGorry PD, McFarlane CA, Patton GC. The Pace Clinic: Development of a Clinical Service for Young People at High Risk of Psychosis. Australasian Psychiatry. 1995;3:345–349.

    Article  Google Scholar 

  57. Fusar-Poli P, Schultze-Lutter F, Cappucciati M, Rutigliano G, Bonoldi I, Stahl D, et al. The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. Schizophrenia Bulletin. 2016;42:732–743.

    Article  PubMed  Google Scholar 

  58. Koutsouleris N, Riecher-Rossler A, Meisenzahl EM, Smieskova R, Studerus E, Kambeitz-Ilankovic L, et al. Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophrenia Bulletin. 2015;41:471–482.

    Article  PubMed  Google Scholar 

  59. Lavoie S, Berger M, Schlogelhofer M, Schafer MR, Rice S, Kim S, et al. Erythrocyte glutathione levels as long-term predictor of transition to psychosis. Translational Psychiatry. 2017;7:1–5.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Medizinische Psychologie, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Deutschland

    Sven Wasserthal M. Sc. & Johannes Schultz Ph. D

  2. Abteilung für Medizinische Psychologie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Bonn, Bonn, Deutschland

    Christian Kloss M. Sc. Psych. &  René Hurlemann

Authors
  1. Sven Wasserthal M. Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Kloss M. Sc. Psych.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. René Hurlemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Johannes Schultz Ph. D
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Finanzierung

Diese Arbeit wurde zum Teil von dem BMBF-geförderten Projekt ESPRIT (Kennzeichen 01EE1407A) finanziert.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wasserthal, S., Kloss, C., Hurlemann, R. et al. N-Acetylcystein: neue Option zur frühen Bekämpfung von Schizophrenie. DNP 19, 28–34 (2018). https://doi.org/10.1007/s15202-018-1942-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15202-018-1942-5

Search

Navigation